Cause and Importance of the Age-dependent Sarcopenia

Cause and Importance of the Age-dependent Sarcopenia With a Blood Based Bioenergetics & Cytokine Profiling Approach

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02994901

Acronym

SARCOPENIA

Enrollment

150

Registered

2016-12-16

Start date

2016-11-01

Completion date

2017-07-30

Last updated

2020-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Keywords

Sarcopenia, Geriatrics, Biomarker

Brief summary

The goal of this cross-sectional study is to evaluate the difference in cytokine profiling approach and mitochondrial function between geriatric sarcopenic patients (group 1) and geriatric non-sarcopenic patients (group 2) and healthy (group 3) geriatric participants.

Detailed description

Study participants (group 1&2) are assessed during the hospital stay and age-matched controls (group 3) will be recruited through Flyers. The investigators aim to isolate and cryopreserve peripheral blood mononuclear cells (PBMCs) from whole blood to perform functional assays on mitochondrial respiratory capacity and ROS. Furthermore, the investigators will investigate the association between biomarkers and frailty, quality of life, functional performance, fatigue and risk of depression. The investigators hypothesize that this profiling approach will allow the evaluation of the progression of age-dependent sarcopenia and uncover novel therapeutic targets.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

60 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* Age between 60 and 85 years * Informed written consent * Normal cognitive status according to Mini-Mental State Examination (MMSE ≥ 24 points) * Life expectancy of \> 3 months according to treating doctor * without implanted Defibrillation * without acute Sepsis * without neurodegenerative diseases, especially amyotrophic lateral sclerosis (ALS) and Huntington

Exclusion criteria

* Age \< 60 years or \> 85 years * Lack of informed written consent * Low cognitive status according to Mini-Mental State Examination (MMSE \< 24 points) * Life expectancy of \< 3 months according to treating doctor * Implanted Defibrillation * Acute Sepsis * neurodegenerative diseases, especially amyotrophic lateral sclerosis (ALS) and Huntington

Design outcomes

Primary

Measure	Time frame
Differences in mitochondrial respiratory capacity of peripheral blood mononuclear cells (PBMCs) using Oxygraph-2k respirometry	Baseline

Secondary

Measure	Time frame
Quality of life (validated questionnaire)	Baseline
Frailty Status according to Fried et.al. criteria	Baseline
Functional limitations (single validated questionnaire)	Baseline

Countries

Germany

Outcome results